Brief: Kiora Pharmaceuticals Receives Approval For Phase 2 Study Of Kio-101 For Treatment Of Ocular Presentation Of Autoimmune Diseases
07/02/2023 12:06
Feb 7 (Reuters) - Kiora Pharmaceuticals Inc KPRX.O :
* KIORA PHARMACEUTICALS RECEIVES APPROVAL FOR PHASE 2 STUDY
OF
KIO-101 FOR TREATMENT OF OCULAR PRESENTATION OF AUTOIMMUNE
DISEASES
* KIORA PHARMACEUTICALS INC - STUDY IS EXPECTED TO BEGIN
ENROLLING PATIENTS IN AUSTRALIA IN THE FIRST HALF OF 2023
Further company coverage: KPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing